Esophageal carcinoma advances in treatment results for locally advanced disease: Review

Annals of Oncology

Volumn 23, Issue 5, 2012, Pages 1095-1103

  Herskovic, A ^a   Russell, W ^a   Liptay, M ^a   Fidler, M J ^a   Al Sarraf, M ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Chemoradiotherapy; Chemotherapy; Esophageal cancers; Radiotherapy; Surgery

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; IRINOTECAN; MITOMYCIN C; PACLITAXEL; TRASTUZUMAB; VINBLASTINE;

ADVANCED CANCER; BRACHYTHERAPY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; DISEASE FREE SURVIVAL; DRUG EFFICACY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; ESOPHAGUS CARCINOMA; ESOPHAGUS RESECTION; HUMAN; INTERMETHOD COMPARISON; LUNG CANCER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSTOPERATIVE CARE; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; REVIEW; SURGICAL MORTALITY; TRACHEOESOPHAGEAL FISTULA; TREATMENT RESPONSE;

CARCINOMA; CHEMORADIOTHERAPY; CHOICE BEHAVIOR; COMBINED MODALITY THERAPY; DIGESTIVE SYSTEM SURGICAL PROCEDURES; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; HUMANS; MEDICAL ONCOLOGY; THERAPIES, INVESTIGATIONAL;

EID: 84860473127     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr433     Document Type: Review

References (145)

1. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83(10): 2049-2053.
2. Ward EM, Thun MJ, Hannan LM et al. Interpreting cancer trends. Ann N Y Acad Sci 2006; 1076: 29-53.
3. Parkin DM, Pisarie P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999; 49(1): 33-64.
4. Herskovic A, Martz K, Al-Sarraf M et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992; 326: 1593-1598.
5. Al-Sarraf M, Martz K, Herskovic A et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 1997; 15: 277-284.
6. Tachibana M, Kinugasa S, Dhar DK et al. Prognostic factors after extended esophagectomy for squamous cell carcinoma of the thoracic esophagus. J Surg Oncol 1999; 72: 88-93.
7. Eloubeidi MA, Desmond R, Arguedas MR et al. Prognostic factors for the survival of patients with esophageal carcinoma in the US: the importance of tumor length and lymph node status. Cancer 2002; 95: 1434-1443.
8. Bollschweiler E, Baldus SE, Schroder W et al. Staging of esophageal carcinoma: length of tumor and number of involved regional lymph nodes. Are these independent prognostic factors? J Surg Oncol 2006; 94: 355-363.
9. Yendamuri S, Swisher SG, Correa AM et al. Esophageal tumor length is independently associated with long-term survival. Cancer 2009; 115: 508-516.
10. Wayman J, Bennett MK, Raimes SA et al. The pattern of recurrence of adenocarcinoma of the oesophago-gastric junction. Br J Cancer 2002; 86: 1223-1229.
11. von Rahden BH, Stein HJ, Feith M et al. Lymphatic vessel invasion as a prognostic factor in patients with primary resected adenocarcinomas of the esophagogastric junction. J Clin Oncol 2006; 23: 874-879.
12. Ancona E, Ruol A, Santi S et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer 2001; 91: 2165-2174.
13. Urba SG, Orringer MB, Turrisi A et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 2001; 19: 305-313.
14. Brucher BLDM, Stein HJ, Zimmermann F et al. Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial. Eur J Surg Oncol 2004; 30: 963-971.
15. Chirieac LR, Swisher SG, Ajani JA et al. Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer 2005; 103: 1347-1355.
16. Brucher BLDM, Becker K, Lordick F et al. The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. Cancer 2006; 106: 2119-2127.
17. Ginsberg GG, Fleisher DE. Tumors of the esophagus. In Long JD, Orlando RC (eds), Schleisenger and Fordtran's: Gastrointestinal and Liver Diseases, 8th edition. Saunders 2006; 949-978.
18. Era M, Cameron AJ, Trastek VF et al. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 1993; 104: 510-513.
19. El-Rifai W, Frierson HF Jr, Moskaluk CA et al. Genetic differences between adenocarcinomas arising in Barrett's esophagus and gastric mucosa. Gastroenterology 2001; 121: 592-598.
20. Metzger R, Schneider PM, Warnecke-Eberz U et al. Molecular biology of esophageal cancer. Onkologie 2004; 27: 200-206.
21. Warnecke EU, Vailbohmer D, Alaks H et al. ERCC-1 and XRCC-1 gene polymorphisms predict response to neoadjuvant radio chemotherapy in esophageal cancer. J Gastrointest Surg 2009; 13: 1411-1421.
22. Maru DM, Luthra R, Correa AM et al. Frequent loss of heterogeneity of chromosome 1q in esophageal adenocarcinoma loss of chromosome 1q 21.3 with shorter overall survival. Cancer 2009; 115: 1576-1585.
23. Schauer M, Janssen KP, Rimkus C et al. Microarray based response prediction in esophageal adenocarcinoma. Clin Cancer Res 2010; 16: 330-337.
24. Lightdale CJ, Kulkarni KG. Role of endoscopic ultrasonography in the staging and follow-up of esophageal cancer. J Clin Oncol 2005; 23: 4483-4489.
25. Weber WA, Ott K, Becker K et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001; 19: 3058-3065.
26. Ott K, Weber WA, Lordick F et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 2006; 24: 4692-4698.
27. Lordick F, Ott K, Krause B-J et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 2007; 8: 797-805.
28. Blackstock AW, Farmer MR, Lovato J et al. A prospective evaluation of the impact of 18-F-fluorodeoxy-D-glucose positron emission tomography staging on survival for patients with locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys 2006; 64: 455-460.
29. Levine EA, Farmer MR, Clark P et al. Predictive value of 18-fluorodeoxy-glucose-positron emission tomography (18F-FDG-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann Surg 2006; 243: 472-478.
30. Rizk NP, Tang L, Adusumilli PS et al. Predictive value of initial PET-SUV max in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma. J Thorac Oncol 2009; 4: 875-879.
31. Song SY, Kim JH, Ryu JS et al. FDG-FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer. Int J Radiat Oncol Biol Phys 2005; 63: 1053-1059.
32. Swisher SG, Erasmus J, Maish M et al.2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer 2004; 101: 1776-1785.
33. Monjazeb AM, Riedlinger G, Aklilu M et al. Outcomes of patients with esophageal cancer staged with [18F] fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection? J Clin Oncol 2010; 28: 2714-2721.
34. Kranzfelder M, Schuster T, Geinitz H et al. Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for esophageal squamous cell cancer. Br J Surg 2011; 98: 768-783.
35. Steyerberg EW, Neville BA, Koppert LB et al. Surgical mortality in patients with esophageal cancer: development and validation of a simple risk score. J Clin Oncol 2006; 24: 4277-4284.
36. Earlam R, Cunha-Melo JR. Oesophageal squamous cell carcinoma. I. A critical review of surgery. Br J Surg 1980; 67: 381-390.
37. Orringer MB, Marshall B, Chang AC et al. Two thousand transhiatal esophagectomies: changing trends, lessons learned. Ann Surg 2007; 246: 363-374.
38. Goldminc M, Madden G, Leprise E et al. Oesphagectomy by a transhiatal approach or thoracotomy a randomized trial. Br J Surg 1993; 80: 367-370.
39. Hulscher JB, van Sandick JW, de Boer AG et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 2002; 347: 1662-1669.
40. Peyre CG, Hagen JA, DeMeester SR et al. The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg 2008; 248: 549-556.
41. Hu Y, Hu C, Zhang H et al. How does the number of resected lymph nodes influence TMN staging and prognosis for esophageal cancer. Ann Surg Oncol 2010; 17: 784-790.
42. Rizk N, Venkatraman E, Park B et al. The prognostic importance of the number of involved lymph nodes in esophageal cancer: implications for revisions of the American Joint Committee on Cancer staging system. J Thorac Cardiovasc Surg 2006; 132: 1374-1381.
43. Wilson M, Rosato EL, Chojnacki KA et al. Prognostic significance of lymph node metastases and ratio in esophageal cancer. J Surg Res 2008; 146: 11-15.
44. Mariette C, Piessen G, Briez N et al. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. Ann Surg 2008; 247: 365-371.
45. Kang CH, Kim YT, Jeon SH et al. Lymphadenectomy extent is closely related to long-term survival in esophageal cancer. Eur J Cardiothorac Surg 2007; 31: 154-160.
46. Altorki NK, Zhou XK, Stiles B et al. Total number of resected lymph nodes predicts survival in esophageal cancer. Ann Surg 2008; 248: 221-226.
47. Greenstein AJ, Litle VR, Swanson SJ et al. Effect of the number of lymph nodes sampled on postoperative survival of lymph node-negative esophageal cancer. Cancer 2008; 112: 1239-1246.
48. Schwarz RE, Smith DD. Clinical impact of lymphadenectomy extent in resectable esophageal cancer. J Gastrointest Surg 2007; 11: 1384-1393; discussion 1393-1394.
49. Sun DR. Ten-year follow-up of esophageal cancer treated by radical radiation therapy: analysis of 869 patients. Int J Radiat Oncol Biol Phys 1989; 16: 329-334.
50. Okawa T, Kita M, Tanaka M et al. Results of radiotherapy for inoperable locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys 1989; 17: 49-54.
51. Nakayama K, Orihata H, Yamaguchi K. Surgical treatment combined with preoperative concentrated irradiation for esophageal cancer. Cancer 1967; 20: 778-788.
52. Nygaard K, Hagen S, Hansen HS et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy. The second Scandinavian trial in esophageal cancer. World J Surg 1992; 16: 1104-1109; discussion 1110.
53. Launois B, Delarue D, Campion JP et al. Preoperative radiotherapy for carcinoma of the esophagus. Surg Gynecol Obstet 1981; 153: 690-692.
54. Gignoux M, Roussel A, Paillot B et al. The value of preoperative radiotherapy in esophageal cancer: results of a study of the E.O.R.T.C. World J Surg 1987; 11: 426-432.
55. Wang M, Gu XZ, Yin WB et al. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of esophageal carcinoma: report on 206 patients. Int J Radiat Oncol Biol Phys 1989; 16: 325-327.
56. Arnott SJ, Duncan W, Kerr GR et al. Low dose preoperative radiotherapy for carcinoma of the oesophagus: results of a randomized clinical trial. Radiother Oncol 1992; 24: 108-113.
57. Huang GJ, Gu XZ, Wang LJ et al. Combined preoperative radiation and surgery for esophageal carcinoma. In Delarue NC (ed): International Trends in General Thoracic Surgery. St Louis, MO: C.V. Mosby 1988;; 315.
58. Kasai M, Mori S, Watanabe T. Follow-up results after resection of thoracic esophageal carcinoma. World J Surg 1978; 2: 543-551.
59. Fok M, Sham JS, Choy D et al. Postoperative radiotherapy for carcinoma of the esophagus: a prospective, randomized controlled study. Surgery 1993; 113: 138-147.
60. Teniere P, Hay JM, Fingerhut A et al. Postoperative radiation therapy does not increase survival after curative resection for squamous cell carcinoma of the middle and lower esophagus as shown by a multicenter controlled trial. French University Association for Surgical Research. Surg Gynecol Obstet 1991; 173: 123-130.
61. Agha FP, Gennis MA, Orringer MB et al. Evaluation of response to preoperative chemotherapy in esophageal and gastric cardia cancer using biphasic esophagrams and surgical pathologic correlation. Am J Clin Oncol 1986; 9: 227-232.
62. Forastiere AA, Gennis M, Orringer MB et al. Cisplatin, vinblastine, and mitoguazone chemotherapy for epidermoid and adenocarcinoma of the esophagus. J Clin Oncol 1987; 5: 1143-1149.
63. Schlag P, Herrmann R, Raeth V et al. Preoperative chemotherapy in esophageal cancer. A phase II study. Acta Oncol 1988; 27: 811-814.
64. Hilgenberg AD, Carey RW, Wilkins EW Jr et al. Preoperative chemotherapy, surgical resections, and selective post operative therapy for squamous cell carcinoma of the esophagus. Ann Thorac Surg 1988; 45: 357-363.
65. Kies MS, Rosen ST, Tsang TK et al. Cisplatin and 5-fluorouracil in the primary management of squamous esophageal cancer. Cancer 1987; 60: 2156-2160.
66. Carey RW, Hilgenberg AD, Choi NC et al. A pilot study of neoadjuvant chemotherapy with 5-fluorouracil and cisplatin with surgical resection and postoperative radiation therapy and/or chemotherapy in adenocarcinoma of the esophagus. Cancer 1991; 68: 489-492.
67. Ajani JA, Roth JA, Ryan B et al. Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction. J Clin Oncol 1990; 8: 1231-1238.
68. Ajani JA, Ryan B, Rich TA et al. Prolonged chemotherapy for localised squamous carcinoma of the oesophagus. Eur J Cancer 1992; 28A: 880-884.
69. Ajani JA, Roth JA, Putnam JB et al. Feasibility of five courses of pre-operative chemotherapy in patients with resectable adenocarcinoma of the oesophagus or gastrooesophageal junction. Eur J Cancer 1995; 31A: 665-670.
70. Imdahl A, Bognar G, Schulte-Monting J et al. Predictive factors for response to neoadjuvant therapy in patients with oesophageal cancer. Eur J Cardiothorac Surg 2002; 21: 657-663.
71. Archer VR, Mulholland PJ, Stocken DD et al. Combined results from three phase II trials of neoadjuvant chemotherapy in operable adenocarcinoma of the oesophagus. Clin Oncol (R Coll Radiol) 2001; 13: 164-169.
72. Carey RW, Hilgenberg AD, Wilkins EW Jr et al. Long-term follow-up of neoadjuvant chemotherapy with 5-fluorouracil and cisplatin with surgical resection and possible postoperative radiotherapy and/or chemotherapy in squamous cell carcinoma of the esophagus. Cancer Invest 1993; 11: 99-105.
73. Kelsen DP, Ginsberg R, Pajak TF et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998; 339: 1979-1984.
74. Kelsen DP, Winter KA, Gunderson LL et al. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 2007; 25: 3719-3725.
75. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomized controlled trial. Lancet 2002; 359: 1727-1733.
76. Allum WH, Stenning SP, Bancewicz J et al. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 2009; 27: 5062-5067.
77. Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
78. Boige V, Pignon J, Saint-Aubert B et al. Final results of a randomized trial comparing preoperative 5-fluorouracil (F)/cisplatin (P) to surgery alone in adenocarcinoma of stomach and lower esophagus (ASLE): FNLCC ACCORD07-FFCD 9703 trial. J Clin Oncol 2007; 25: 18S (Abstr 4510).
79. Gebski V, Burmeister B, Smithers BM et al. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a metaanalysis. Lancet Oncol 2007; 8: 226-234.
80. Thirion P, Michiels S, Le Maître A et al. Individual patient data-based metaanalysis assessing pre-operative chemotherapy in resectable oesophageal carcinoma. J Clin Oncol 2007; 25: 18S (Abstr 4512).
81. Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Sem Radiat Oncol 2007; 17: 2-9.
82. Byfield JE. 5-fluorouracil radiation sensitization: a brief review. Invest New Drugs 1989; 7: 111-116.
83. Byfield JE, Calabro-Jones P, Klisak I et al. Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-fluorouracil or ftorafur and X rays. Int J Radiat Oncol Biol Phys 1982; 8: 1923-1933.
84. Lawrence TS, Tepper JE, Blackstock AW. Fluoropyrimidine-radiation interactions in cells and tumors. Semin Radiat Oncol 1997; 7: 260-266.
85. Dewit L. Combined treatment of radiation and cisdiamminedichloroplatinum (II): a review of experimental and clinical data. Int J Radiat Oncol Biol Phys 1987; 13: 403-426.
86. Chen AY, Choy H, Rothenberg ML. DNA topoisomerase I-targeting drugs as radiation sensitizers. Oncology (Williston Park) 1999; 13 (suppl): 39-46.
87. Creane M, Seymour CB, Colucci S et al. Radiobiological effects of docetaxel (Taxotere): a potential radiation sensitizer. Int J Radiat Biol 1999; 75: 731-737.
88. Hennequin C. Association of taxanes and radiotherapy: preclinical and clinical studies. Cancer Radiother 2004; 8 (suppl): S95-S105.
89. Kirichenko AV, Travis EL, Rich TA. Radiation enhancement by 9-aminocamptothecin: evidence for improved therapeutic ratio with a multiple dose schedule. Ann N Y Acad Sci 1996; 803: 312-314.
90. Franklin R, Steiger Z, Vaishampayan G et al. Combined modality therapy for esophageal squamous cell carcinoma. Cancer 1983; 51: 1062-1071.
91. Leichman L, Steiger Z, Seydel HG et al. Preoperative chemotherapy and radiation therapy for patients with cancer of the esophagus: a potentially curative approach. J Clin Oncol 1984; 2: 75-79.
92. Poplin E, Fleming T, Leichman L et al. Combined therapies for squamous-cell carcinoma of the esophagus, a Southwest Oncology Group Study (SWOG-8037). J Clin Oncol 1987; 5: 622-628.
93. Posner MC, Gooding WE, Landreneau RJ et al. Preoperative chemoradiotherapy for carcinoma of the esophagus and gastroesophageal junction. Cancer J Sci Am 1998; 4: 237-246.
94. Shahab N, Wilkes J, Beyer S et al. Neoadjuvant chemoradiation followed by transhiatal esophagectomy for regional/locally advanced esophageal carcinoma. Proc Am Soc Clin Oncol 1996; 17: 259a.
95. Jones DR, Detterbeck FC, Egan TM et al. Induction chemoradiotherapy followed by esophagectomy in patients with carcinoma of the esophagus. Ann Thorac Surg 1997; 64: 185-191; discussion 191-192.
96. Nesbitt J, Ajani JA, Komaki R et al. Preoperative taxol-based chemotherapy (CT) followed by chemoradiation therapy (CTRT) in patients (PTS) with potentially resectable esophageal carcinoma (EC). Proc Am Soc Clin Oncol 1998; 17: 282a.
97. Safran H, Gaissert H, Akerman P et al. Neoadjuvant paclitaxel, cisplatin and radiation for esophageal cancer. Proc Am Soc Clin Oncol 1998; 17: 259a.
98. Forastiere AA, Orringer MB, Perez-Tamayo C et al. Concurrent chemotherapy and radiation therapy followed by transhiatal esophagectomy for local-regional cancer of the esophagus. J Clin Oncol 1990; 8: 119-127.
99. Urba SG, Orringer MB, Perez-Tamayo C et al. Concurrent preoperative chemotherapy and radiation therapy in localized esophageal adenocarcinoma. Cancer 1992; 69: 285-291.
100. Forastiere AA. Treatment of locoregional esophageal cancer. Semin Oncol 1992; 19 (suppl 11): 57-63.
101. Heath EI, Burtness BA, Heitmiller RF et al. Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. J Clin Oncol 2000; 18: 868-876.
102. Ajani JA, Komaki R, Putnam JB et al. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer 2001; 92: 279-286.
103. Slater MS, Holland J, Faigel DO et al. Does neoadjuvant chemoradiation downstage esophageal carcinoma? Am J Surg 2001; 181: 440-444.
104. Laterza E, de'Manzoni G, Tedesco P et al. Induction chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus: long-term results of a phase II study. Ann Surg Oncol 1999; 6: 777-784.
105. Forastiere AA, Heitmiller RF, Lee DJ et al. Intensive chemoradiation followed by esophagectomy for squamous cell and adenocarcinoma of the esophagus. Cancer J Sci Am 1997; 3: 144-152.
106. Adelstein DJ, Rice TW, Becker M et al. Concurrent chemotherapy (CCT), accelerated fractionated radiation (AFR) and surgery for esophageal cancer. Proc Am Soc Clin Oncol 1996; 15: 203a.
107. Raoul JL, Le Prise E, Meunier B et al. Neoadjuvant chemotherapy and hyperfractionated radiotherapy with concurrent low-dose chemotherapy for squamous cell esophageal carcinoma. Int J Radiat Oncol Biol Phys 1998; 42: 29-34.
108. Adelstein DJ, Rice TW, Becker M et al. Use of concurrent chemotherapy, accelerated fractionation radiation, and surgery for patients with esophageal carcinoma. Cancer 1997; 80: 1011-1020.
109. Stahl M, Wilke H, Fink U et al. Combined preoperative chemotherapy and radiotherapy in patients with locally advanced esophageal cancer: interim analysis of a phase II trial. J Clin Oncol 1996; 14: 829-837.
110. Nguyen NP, Leonardo JM, Karlsson U et al. Preoperative chemotherapy and radiation for advanced esophageal carcinoma: comparison between once a day radiation and hyperfractionation, a single-institution experience. Am J Clin Oncol 2002; 25: 358-364.
111. Bates BA, Detterbeck FC, Bernard SA et al. Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma. J Clin Oncol 1996; 14: 156-163.
112. Gaspar LE, Winter K, Kocha WI et al. A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report. Cancer 2000; 88: 988-995.
113. Cooper JS, Guo MD, Herskovic A et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01)-Radiation Therapy Oncology Group. JAMA 1999; 281: 1623-1627.
114. Smith TJ, Ryan LM, Douglass HO Jr et al. Combined chemoradiotherapy vs. radiotherapy alone for early stage squamous cell carcinoma of the esophagus: a study of the Eastern Cooperative Oncology Group. Int J Radiat Oncol Biol Phys 1998; 42: 269-276.
115. Minsky BD, Pajak TF, Ginsberg RJ et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002; 20: 1167-1174.
116. Crehange G, Maingon P, Peignaux K et al. Phase III trial of protracted compared with split-course chemoradiation for esophageal carcinoma: Fé dé ration Francophone de Cancé rologie Digestive 9102. J Clin Oncol 2007; 25: 4895-4901.
117. Adelstein DJ, Rice TW, Rybicki LA et al. Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy. J Clin Oncol 2000; 18: 2032-2039.
118. Safran H, Gaissert H, Akerman P et al. Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer. Cancer Invest 2001; 19: 1-7.
119. Bains MS, Stojadinovic A, Minsky B et al. A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: initial results. J Thorac Cardiovasc Surg 2002; 124: 270-277.
120. Urba SG, Orringer MB, Ianettonni M et al. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal carcinoma. Cancer 2003; 98: 2177-2183.
121. van Meerten E, Muller K, Tilanus HW et al. Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study. Br J Cancer 2006; 94: 1389-1394.
122. Meluch AA, Greco FA, Gray JR et al. Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: final results of a Minnie Pearl Cancer Research Network phase II trial. Cancer J 2003; 9: 251-260.
123. Pasini F, de Manzoni G, Pedrazzani C et al. High pathological response rate in locally advanced esophageal cancer after neoadjuvant combined modality therapy: dose finding of a weekly chemotherapy schedule with protracted venous infusion of 5-fluorouracil and dose escalation of cisplatin, docetaxel and concurrent radiotherapy. Ann Oncol 2005; 16: 1133-1139.
124. Lin C-C, Hsu C-H, Cheng JC et al. Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol 2007; 18: 93-98.
125. Kelsey Cr, Chino JP, Willett CG et al. Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer. Int J Radiat Oncol Biol Phys 2007; 69: 770-776.
126. Berger AC, Farma J, Scott WJ et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 2005; 23: 4330-4337.
127. Walsh TN, Noonan N, Hollywood D et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996; 335: 462-467.
128. Burmeister BH, Smithers BM, Gebski V et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomized controlled phase III trial. Lancet Oncol 2005; 6: 659-668.
129. Tepper J, Krasna MJ, Niedzwiecki D et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008; 26: 1086-1092.
130. Le Prise E, Etienne PL, Meunier B et al. A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer 1994; 73: 1779-1784.
131. Apinop C, Puttisak P, Preecha N. A prospective study of combined therapy in esophageal cancer. Hepatogastroenterology 1994; 41: 391-393.
132. Bosset JF, Gignoux M, Triboulet JP et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997; 337: 161-167.
133. Lee JL, Park SI, Kim SB et al. A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol 2004; 15: 947-954.
134. Urschel JD, Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg 2003; 185: 538-543.
135. Malthaner RA, Wong RK, Rumble RB, Zuraw L. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis. BMC Med 2004; 2: 35.
136. Bedenne L, Michel P, Bouché O et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007; 25: 1160-1168.
137. Mariette C, Seitz JF, Maillard E et al. Surgery alone versus chemoradiotherapy followed by surgery for localized esophageal cancer: analysis of a randomized controlled phase III trial FFCD 9901. J Clin Oncol 2010; 28 (suppl): 15s (Abstr 4005).
138. Gaast AV, van Hagen OP, Hulshof M et al. Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: results for a multicenter randomized phase III study. J Clin Oncol 2010; 28 (suppl): 15s (Abstr 4004).
139. Bonnetain F, Bouche O, Michel OP et al. A comparative longitudinal quality of life study using the Spitzer quality of life index in a randomized multicenter phase III trial (FFCD 9102): chemoradiation followed by surgery compared with chemoradiation alone in locally advanced squamous resectable thoracic esophageal cancer. Ann Oncol 2006; 17: 827-834.
140. Ajani JA, Walsh G, Komaki R et al. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer 2004; 100: 2347-2354.
141. Ruhstaller T, Widmer L, Schuller JC et al. Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02). Ann Oncol 2009; 20: 1522-1528.
142. Stahl S, Walz MK, Stuschke M et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009; 27: 851-856.
143. Campbell N, Villaflor VM. Neoadjuvant treatment of esophageal cancer. World J Gastroenterol 2010; 16(30): 3793-3808.
144. Gore E, Curry A, Choong N. Tracheoesophageal fistula associated with bevacizumab 21 months after completion of radiation therapy. Thor Oncol 2009; 4: 1590-1591.
145. Spiegel DR, Hainsworth JD, Yardley DA et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiaiton and bevacizumab. J Clin Oncol 2010; 28: 43-48.